i3 has entered into an agreement with Acurian, to provide study sponsors with a solution to recruit investigators for clinical trials. Acurian’s patient database will be complemented by new i3 services that offer statistics for improved planning and identification of trial sites with greater access to appropriate patient populations.
Reportedly, i3 can identify potential investigators throughout the US and rank them according to the number of patients available who match the required study-specific criteria.
Tom Abbott, president of i3 Pharma Informatics, said: “Pairing i3’s clinical informatics solutions with Acurian’s patient assets will offer a unique product to the marketplace and particularly benefit sponsors of studies anticipating or experiencing enrollment issues. It also represents an additional opportunity to increase i3’s brand penetration among pharmaceutical, biotech, and medical device sponsors.”
Bill Gwinn, vice president of clinical informatics at i3 Pharma Informatics, said: “This agreement will further cement our reputation as a clinical research organization on which sponsors rely to execute difficult trials. 78,000 investigators in i3’s US database, combined with more than 50 million patients in Acurian’s database, will yield a comprehensive view of sites, investigators, and patients to help our customers achieve their enrollment targets.”
Content from our partners
